Drugs / Fresolimumab
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03064074 | Nov 2017 → Jul 2022 | osteogenesis imperfecta | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01284322 | Jan 2011 → Jun 2013 | diffuse scleroderma | Boston University | Completed | No outcome recorded |
| Phase 1 | NCT00464321 | May 2007 → Jan 2010 | focal segmental glomerulosclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00356460 | Sep 2006 → May 2009 | melanoma, renal cell carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00923169 | Jul 2006 → Jan 2010 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00125385 | Jul 2005 → Sep 2008 | idiopathic pulmonary fibrosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02581787 | Aug 2016 → Mar 2023 | non-small cell lung carcinoma | Maximilian Diehn | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01665391 | Aug 2012 → Jun 2014 | primary focal segmental glomerulosclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01472731 | Dec 2011 → Nov 2012 | primary brain neoplasm | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT01401062 | Jul 2011 → Jun 2014 | breast cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01112293 | Apr 2010 → Oct 2012 | malignant pleural mesothelioma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fresolimumab | “Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.” PMID 24618589 ↗ Mar 2014 |
| Known as | GC 1008 | “GC1008 is a human IgG4 monoclonal antibody that neutralizes all isoforms of TGFBeta.” NCT00923169 ↗6“Anti-Transforming Growth Factor-beta (GC 1008)” NCT00923169 ↗ |
| Known as | GZ-402669 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743022 ↗ |
| Action | Inhibit | “Transforming growth factor beta-3 inhibitor” CHEMBL1743022 ↗3“Transforming growth factor beta-1 inhibitor” CHEMBL1743022 ↗ “Transforming growth factor beta-2 inhibitor” CHEMBL1743022 ↗ “an antibody that neutralizes TGFb” NCT00125385 ↗ |
| Modality | Protein / enzyme biologic | “GC1008, an antibody that neutralizes TGFb” NCT00125385 ↗ |
| Route | Intravenous | “0.3 mg/kg, IV on Day 0” NCT00125385 ↗ |
| Target | TGFB1 | “Transforming growth factor beta-1 inhibitor” CHEMBL1743022 ↗ |
| Target | TGFB2 | “Transforming growth factor beta-2 inhibitor” CHEMBL1743022 ↗ |
| Target | TGFB3 | “Transforming growth factor beta-3 inhibitor” CHEMBL1743022 ↗ |